Bicara Therapeutics Inc. (BCAX) stock
BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.60−0.15 (-1.54%)
Close on Nov 17, 2026Market cap $635.26MP/E –Yield –
Bicara Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Bicara Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$161.73M. For fiscal 2025 it was -$106.83M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$106.83M | – |
| FY2024 | Dec 31, 2024 | -$74.75M | – |
| FY2023 | Dec 31, 2023 | -$45.63M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$56.13M | – |
| Q2 FY2026 | Jun 30, 2026 | -$44.21M | – |
| Q1 FY2026 | Mar 31, 2026 | -$37.51M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.89M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.25M | – |
| Q2 FY2025 | Jun 30, 2025 | -$25.59M | – |
| Q1 FY2025 | Mar 31, 2025 | -$28.11M | – |
| Q4 FY2024 | Dec 31, 2024 | -$30.03M | – |
| Q3 FY2024 | Sep 30, 2024 | -$17.22M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.91M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.59M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.04M | – |
See a number that looks wrong?